Novo Nordisk has announced headline results from Semaglutide Treatment Effect in People with obesity (STEP) 1, a phase 3a trial in the STEP programme, which revealed the study met both primary endpoints.

Fractyl Laboratories has received approval from the FDA of an Investigational Device Exemption (IDE) to begin a pivotal study of Revita DMR in type 2 diabetes (T2D) patients treated with insulin.